Accreditation Statistics

As of May 2, 2024

Cellular Therapy Entities

  • Accredited: 262
  • Applicants: 30

Cord Blood Banks

  • Accredited: 48
  • Applicants: 10


Initial Accreditations

  • Abu Dhabi Stem Cell Center, Abu Dhabi, United Arab Emirates | Cellular Therapy Product Processing with Minimal Manipulation
  • CHN - Complexo Hospitalar de Niterói, Rio de Janeiro, Brazil | Adult and Pediatric Allogeneic and Autologous Hematopoietic Progenitor Cell Transplantation, Marrow and  Peripheral Blood Cellular Therapy Product Collection, and Cellular Therapy Product Processing with Minimal Manipulation


A complete list of accredited organizations can be found at

Tata Medical Center is First Cellular Therapy Program in India to Earn FACT Accreditation

Posted in :: 2024 Volume 2 :: Tuesday, April 9th, 2024

FACT is pleased to announce that Tata Medical Center in Kolkata, India, received internationally recognized FACT accreditation. Directed by Jeevan Kumar, MD, MBBS, it is the first and only cellular therapy program in India to be recognized by FACT. Dr. Mammen Chandy, former Director of Tata Medical Center, committed years ago to enhancing quality throughout the program and attaining FACT accreditation. The program achieved accreditation February 29, 2024, for Adult and Pediatric Allogeneic and Autologous Hematopoietic Progenitor Cell Transplantation, Peripheral Blood Cellular Therapy Product Collection, and Cellular Therapy Product Processing with Minimal Manipulation. Tata Medical Center is part of the FACT India Working Group, led by Nadim Mahmud, MD, PhD.

Dr. Mahmud states, “This marks a significant milestone for the FACT India Working Group and for India. We are encouraged by Tata Medical Center’s achievement in obtaining FACT accreditation, which demonstrates a commitment to quality and ensuring the best possible outcomes for patients undergoing stem cell transplants. We believe that other transplant centers in India will recognize the benefits and join us in pursuing FACT accreditation. I am indebted to Professor Mammen Chandy from Tata Medical Center for his wisdom in facilitating the process and advocating the need for FACT accreditation, not only for Tata Medical Center in Kolkata, but for all BMT centers in India.”

Dr. Kumar notes, “The FACT accreditation cements our commitment to provide the highest quality of patient care. It is recognition of our founding director’s vision to establish evidence based best practices in cellular therapy at Tata Medical Center. The unwavering support of the administration and our team’s hard work has resulted in successfully completing the accreditation process. It marks the inclusion of the first Indian center into the global consortium of accredited institutions. Even though the accreditation process was rigorous, it helped us to consolidate our strengths and identify opportunities for improvement. The FACT team has continuously supported us in this endeavor. The on-site inspection served as a peer-review by international experts and boosted the morale of our team members. As an active member of the FACT India Working Group, we are happy to share our experiences and quality improvement initiatives with like-minded centers in India and abroad.”

Dr. Phyllis Warkentin, FACT Chief Medical Officer, states, “Tata Medical Center’s achievement of FACT accreditation in Hematopoietic Cell Transplantation and Cellular Therapy as the first program in India to reach this milestone demonstrates its commitment to providing quality care for the patients it serves. FACT commends the leadership and staff of Tata Medical Center for their dedication and resilience in pursuit of accreditation, their contributions to the FACT India Working Group, and their leadership in the field and the region.”

Transporting Cellular Therapy Products Intended for High-Dose Chemotherapy Recipients

Posted in :: 2017 Volume 1 :: Thursday, January 26th, 2017

The FACT-JACIE Hematopoietic Cell Therapy Standards state, “If the intended recipient has received high-dose therapy, the cellular therapy product shall be transported.” (CM10.3.2, C10.3.2, D10.7) Some have asked what the purpose of this standard is because a product always needs to be distributed to the recipient.

The key word in this standard is “transported.” As stated by the FACT-JACIE definitions in Part A of the Standards, “transport” is the physical transfer of a cellular therapy product within or between facilities during which it does not leave the control of trained personnel at the transporting or receiving facility. In other words, someone who is trained to transfer a product must be with it at all times. This is in contrast to shipping, during which the product does leave the control of trained personnel (such as shipment on a commercial distributing company’s truck or airplane).

If a patient has undergone high-dose marrow ablative treatment in preparation for transplant, the cellular therapy product is essential for the patient’s survival since it may not be possible to obtain additional marrow or blood from the original donor or a second donor in time to prevent complications from aplasia. For this reason, it is important that the product be entrusted to a knowledgeable individual who accompanies it from the distributing facility to the receiving facility.

AHCTA Publishes Analysis of Processing Staff Training and Competency Assessment Practices

Posted in :: 2016 Volume I :: Thursday, April 14th, 2016

The Alliance for Harmonization of Cellular Therapy Accreditation (AHCTA) surveyed cell processing facilities worldwide to elicit information about their training and competency assessment programs. Because these programs are critical to the safety of hematopoietic progenitor cell (HPC) products, the survey results are a resource to facilities to establish and maintain a competent workforce.

Results were published in Cytotherapy in Training practices of cell processing laboratory staff: analysis of a survey by the Alliance for Harmonization of Cellular Therapy Accreditation (Taylor, Slaper-Cortenbach, et al, Dec 2015, doi:10.1016/j.jcyt.2015.08.006). Respondents to the survey represented a diverse set of processing facilities and answered questions related to their facility type, location, activity, personnel, and methods used for training and competency.

Data from the survey illustrated a variety of training and competency methods, with some being more common than others. The results may help processing facilities with establishing or improving their training and competency programs.